Printer Friendly

UNIVERSITY OF MICHIGAN RECEIVES $5.5 MILLION FROM WARNER-LAMBERT FOR RESEARCH

 UNIVERSITY OF MICHIGAN RECEIVES $5.5 MILLION
 FROM WARNER-LAMBERT FOR RESEARCH
 ANN ARBOR, Mich., Sept. 24, 1992 -- The Parke-Davis division of Warner-Lambert Company has contributed $5.5 million in support of medical and scientific research at the University of Michigan. One of the largest single grants ever received by the university, it will help fund research in the School of Medicine, College of Pharmacy and Department of Chemistry.
 Three endowed professorships -- the Warner-Lambert/Parke-Davis Professorship in Chemistry and two new Warner-Lambert/Parke-Davis Professorships in Molecular Medicine at the School of Medicine -- will be established with $3.6 million of the gift. Faculty selected for these new positions will conduct research in the fields of basic chemistry, molecular biology, biotechnology, genetics and human gene theory.
 The remaining $1.9 million of the gift will be used to support graduate students in pharmacy and medicine.
 The Warner-Lambert/Parke-Davis Endowment for Graduate Student Aid, a $1 million program, will provide tuition and financial support for two doctoral candidates per year working in the pharmaceutical sciences. Warner-Lambert/Parke-Davis fellowships totaling $900,000 will assist graduate and post graduate students in the study of biotechnology, gene therapy and basic science.
 "This educational partnership between Parke-Davis and the University of Michigan is a model for other corporations and colleges," said U.S. Rep. William Ford of Michigan. "As chairman of the House Committee on Education and Labor, as well as the congressman representing Ann Arbor, I know the financial needs of our colleges. Parke-Davis is to be commended for its faith in the University of Michigan and willingness to step forward to help our students."
 Parke-Davis' support of research and teaching at the University of Michigan began in 1895, when the Parke-Davis research division established a fellowship in chemistry for research in medicinal substances. Parke-Davis continues to maintain close links with its neighbor through adjunct professorships, lectures and seminars.
 "We place a high value on the quantity and quality of the interactions we have with the University in the physical and biological sciences, in pharmaceutical sciences and in medicine," said Ronald M. Cresswell, vice president, and chairman Parke-Davis Pharmaceutical Research. "The ability to collaborate closely with University of Michigan researchers is the main reason our research laboratories are located in Ann Arbor."
 Warner-Lambert, headquartered in Morris Plains, N.J., is a worldwide company devoted to discovering, developing, manufacturing and marketing quality health care and consumer products. It employs approximately 34,000. The company's Parke-Davis Pharmaceutical Research Division employs approximately 1,300 at its worldwide research and development headquarters in Ann Arbor.
 -0- 9/24/92
 /CONTACT: Peter Wolf, 201-540-6696, Sandy Horner, 201-540-4268, both of Warner-Lambert Company/
 (WLA) CO: Warner-Lambert Company ST: New Jersey, Michigan IN: MTC SU:


SM -- NY074 -- 3301 09/24/92 16:57 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 24, 1992
Words:460
Previous Article:SHELL CANADA PRODUCTS OFFICIALLY OPENS PLANT
Next Article:KELSEY-HAYES WHEELS GROUP SETS SIGHTS ON EASTERN EUROPE
Topics:


Related Articles
SURINDER KUMAR ELECTED A WARNER-LAMBERT CORPORATE VICE PRESIDENT
WARNER-LAMBERT REPORTS THIRD-QUARTER SALES AND EARNINGS
LIDAK PHARMACEUTICALS APPOINTS GERALD J. YAKATAN AS VICE PRESIDENT, DRUG DEVELOPMENT
Warner-Lambert Adopts Consilium(R) FlowStream(R) MES as Corporate Standard for Manufacturing Execution Systems
MitoKor Names Dr. Walter H. Moos Chairman And CEO
Warner-Lambert Elects Maurice Renshaw Vice President
Warner-Lambert to Purchase Remaining Interest in Jouveinal
Xenova and Warner-Lambert Agree Further Drug Discovery Collaborations
Aurora Biosciences Announces Completion Of First Stage of UHTSS for Warner-Lambert.
Unigene Laboratories Reports Financial Results for Second Quarter 1999.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters